These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 15901046)
1. In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs. Uckun FM; Qazi S; Venkatachalam TK Arzneimittelforschung; 2005; 55(4):223-31. PubMed ID: 15901046 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates. Uckun FM; Pendergrass S; Qazi S; Venkatachalam TK Arzneimittelforschung; 2004; 54(1):69-77. PubMed ID: 14979612 [TBL] [Abstract][Full Text] [Related]
3. Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses. Uckun FM; Venkatachalam TK; Qazi S Arzneimittelforschung; 2006 Feb; 56(2A):193-203. PubMed ID: 16570827 [TBL] [Abstract][Full Text] [Related]
4. Stampidine as a novel nucleoside reverse transcriptase inhibit with potent anti-HIV activity. Uckun FM Arzneimittelforschung; 2006 Feb; 56(2A):121-35. PubMed ID: 16570821 [TBL] [Abstract][Full Text] [Related]
5. Anti-retroviral activity of GMP-grade stampidine against genotypically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study. Uckun FM; DuMez D; Qazi S; Tibbles H; Venkatachalam TK Arzneimittelforschung; 2007; 57(2):112-21. PubMed ID: 17396622 [TBL] [Abstract][Full Text] [Related]
6. Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations. Uckun FM; Pendergrass S; Venkatachalam TK; Qazi S; Richman D Antimicrob Agents Chemother; 2002 Nov; 46(11):3613-6. PubMed ID: 12384373 [TBL] [Abstract][Full Text] [Related]
7. Phenyl phosphoramidate derivatives of stavudine as anti-HIV agents with potent and selective in-vitro antiviral activity against adenovirus. Uckun FM; Pendergrass S; Qazi S; Samuel P; Venkatachalam TK Eur J Med Chem; 2004 Mar; 39(3):225-34. PubMed ID: 15051170 [TBL] [Abstract][Full Text] [Related]
8. Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. Uckun FM; Cahn P; Qazi S; D'Cruz O Expert Opin Investig Drugs; 2012 Apr; 21(4):489-500. PubMed ID: 22360744 [TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of a thermoreversible ovule formulation of stampidine, a novel nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. D'Cruz OJ; Samuel P; Waurzyniak B; Uckun FM Biol Reprod; 2003 Dec; 69(6):1843-51. PubMed ID: 12890726 [TBL] [Abstract][Full Text] [Related]
10. Unmet challenges in HIV therapy and potential of stampidine. Uckun FM Arzneimittelforschung; 2006 Feb; 56(2A):117-20. PubMed ID: 16570820 [No Abstract] [Full Text] [Related]
11. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Calvez V; Costagliola D; Descamps D; Yvon A; Collin G; Cécile A; Delaugerre C; Damond F; Marcelin AG; Matheron S; Simon A; Valantin MA; Katlama C; Brun-Vézinet F Antivir Ther; 2002 Sep; 7(3):211-8. PubMed ID: 12487389 [TBL] [Abstract][Full Text] [Related]
12. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025 [TBL] [Abstract][Full Text] [Related]
13. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. Merrill DP; Moonis M; Chou TC; Hirsch MS J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296 [TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928 [TBL] [Abstract][Full Text] [Related]
15. Stampidine is a potential nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. D'Cruz OJ; Uckun FM Fertil Steril; 2004 Mar; 81 Suppl 1():831-41. PubMed ID: 15019817 [TBL] [Abstract][Full Text] [Related]
16. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Dubé MP; Parker RA; Mulligan K; Tebas P; Robbins GK; Roubenoff R; Grinspoon SK Clin Infect Dis; 2007 Jul; 45(1):120-6. PubMed ID: 17554712 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, separation and anti-HIV activity of distereoisomers of N-[p-(4-bromophenyl) -2',3'-didehydro-3'-deoxy-5'-thymidylyl]-L-alanine methyl ester (stampidine). Venkatachalam TK; Qazi S; Uckun FM Arzneimittelforschung; 2006 Feb; 56(2A):152-8. PubMed ID: 16570823 [TBL] [Abstract][Full Text] [Related]
19. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy. Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129 [TBL] [Abstract][Full Text] [Related]
20. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine. Gao WY; Johns DG; Tanaka M; Mitsuya H Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]